Posted by Michael Wonder on 12 Jul 2021
Teplizumab awarded Innovation Passport in the United Kingdom for the delay of onset of clinical type 1 diabetes in at risk individuals
12 July 2021 - Designation is the first step in a new MHRA initiative to accelerate the development and access to innovative medicines in the UK post-Brexit.
Provention Bio today announced that teplizumab, an anti-CD3 monoclonal antibody, was awarded an Innovation Passport for the delay of clinical type 1 diabetes in at risk individuals.
Teplizumab is one of the first investigational medicines to receive this designation under the United Kingdom's Innovative Licensing and Access Pathway launched by the MHRA in January 2021.
